Evidence map›Paper›PMID 30237581›Full record

SynthesisThe pharmacogenomics journal2018

Genetic markers in methotrexate treatments.

Andrea Giletti, Patricia Esperon

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The pharmacogenomics journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Journal of clinical medicine · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Pharmacogenomic Profile of Amazonian Amerindians.Journal of personalized medicine · 2022
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Andrea GilettiLaboratorio de Biologia Molecular, Departamento de Bioquimica Clinica, Facultad de Quimica, Universidad de la Republica, Montevideo, Uruguay.ORCID http://orcid.org/0000-0002-6978-8743
Patricia EsperonLaboratorio de Biologia Molecular, Departamento de Bioquimica Clinica, Facultad de Quimica, Universidad de la Republica, Montevideo, Uruguay. pesperon@fq.edu.uy.
Universidad de la República de Uruguay · UY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methotrexate (MTX), a structural analog of folic acid, is widely employed in the treatment of different cancers and autoimmune diseases. Despite the successful results observed, the main disadvantage lies in interpatient variability in the pharmacokinetic and pharmacodynamic parameters. In particular, adverse events and toxicities induced by MTX are a matter of concern and can be the cause of dose reduction or treatment discontinuation. Among the different approaches to reduce MTX therapeutic limitations, pharmacogenomics contributes by considering the effect of inherited genetic differences on those parameters. This review provides an update on MTX pharmacogenomics. It reports the contribution of main gene polymorphisms involved in the influx, efflux, cellular effect, and elimination on MTX toxicity and efficacy, on all the diseases treated with this drug. From the analysis of the data presented in this review, we concluded that only gene polymorphisms MTHFR rs1801133, SLC19A1 rs1051266, and TYMS rs34743033 could influence clinical decision-making.

Indexed as

Pharmacogenomic VariantsPolymorphism, GeneticAntimetabolites, AntineoplasticClinical Decision-MakingHumansImmunosuppressive AgentsMethotrexateMethylenetetrahydrofolate Reductase (NADPH2)Patient SelectionPharmacogeneticsPharmacogenomic TestingPrecision MedicinePredictive Value of TestsReduced Folate Carrier ProteinRisk AssessmentThymidylate SynthaseAntimetabolites, AntineoplasticImmunosuppressive AgentsMethotrexateMethylenetetrahydrofolate Reductase (NADPH2)MTHFR protein, humanReduced Folate Carrier ProteinSLC19A1 protein, humanThymidylate SynthaseTYMS protein, human

Identifiers

PMID30237581
OpenAlexW2890247615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.